Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy AGS-003 + Sunitinib
Indication/Tumor Type renal cell carcinoma
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma no benefit AGS-003 + Sunitinib Phase II Actionable In a Phase II clinical trial, treatment with the combination of AGS-003 and Sutent (sunitinib) resulted in clinical benefit in 62% (13/21) of patients with advanced renal cell carcinoma, with 9 partial responses and 4 patients achieving stable disease, a median overall survival of 30.2 months, and median progression-free survival of 11.2 months (PMID: 25901286). 25901286
Unknown unknown renal cell carcinoma no benefit AGS-003 + Sunitinib Phase III Actionable In a Phase III trial (ADAPT), the combination of AGS-003 (Rocapuldencel-T) and Sutent (sunitinib) did not demonstrate improved efficacy compared to Sutent alone in metastatic renal cell carcinoma patients, resulting in median overall survival of 27.7 v 32.4 months, progression-free survival of 6.0 v 7.83 months, and objective response rate of 42.7% (131/307, 9 complete, 122 partial) v 39.4% (61/155, 3 complete, 58 partial) in the combination or monotherapy groups, respectively (PMID: 32034074; NCT01582672). 32034074
PubMed Id Reference Title Details
(25901286) Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. Full reference...
(32034074) Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Full reference...